Log in to save to my catalogue

Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires...

Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_2424468542

Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial

About this item

Full title

Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial

Publisher

San Francisco: Public Library of Science

Journal title

PLoS pathogens, 2020-06, Vol.16 (6), p.e1008522-e1008522

Language

English

Formats

Publication information

Publisher

San Francisco: Public Library of Science

More information

Scope and Contents

Contents

DNA vectors have been widely used as a priming of poxvirus vaccine in prime/boost regimens. Whether the number of DNA impacts qualitatively or quantitatively the immune response is not fully explored. With the aim to reinforce T-cell responses by optimizing the prime-boost regimen, the multicentric EV03/ANRS VAC20 phase I/II trial, randomized 147 H...

Alternative Titles

Full title

Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_plos_journals_2424468542

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_2424468542

Other Identifiers

ISSN

1553-7374,1553-7366

E-ISSN

1553-7374

DOI

10.1371/journal.ppat.1008522

How to access this item